Anxiety and depression are prevalent among cancer patients, with significant negative impact.
| BACKGROUND
The National Institutes of Mental Health estimates that depression affects nearly 16 million people in the United States (Liu et al., 2015) .
A serious mood disorder, depression is characterized by anhedonia, the reduced ability to experience pleasure, insomnia or hypersomnia, psychomotor agitation or retardation, fatigue, feelings of worthlessness or guilt, difficulty concentrating, and repetitive thoughts of suicide or death.
According to the American Psychiatric Association (2016), more than 25 million people in the United States suffer from anxiety disorders involving persistent, excessive worry or fear of objects or situations, and recurrent panic attacks. Depression and anxiety are especially common in cancer patients (Anderson & Taylor, 2012) and negatively impact quality of life (Brown, Kroenke, Theobald, Wu, & Tu, 2010; Bultz & Carlson, 2005) . One in three patients (32%) experience anxiety, depression, or adjustment disorder, which is characterized by feelings of stress in response to a major event such as a cancer diagnosis. Breast cancer patients were reported to be most affected (42%), followed by those with head and neck cancer (41%) and melanoma (39%). Risk factors for depression include poor performance status, as determined by using a validated version of The Eastern Cooperative Oncology Group Scale to measure functional status, pain, old age, and low-level education, while poor performance status, old age, and female gender were predictors of anxiety (Hong & Tian, 2014; Mols, Husson, Roukema, & van de Poll-Franse, 2013 ).
Depression and anxiety also contribute to long-term strain in cancer patients. In a recent survey of 3,370 survivors, 40% reported moderate to high anxiety, and in approximately 20%, moderate to high levels of depression lasted up to 6 years post-diagnosis (Inhestern et al., 2017) . Depression can lead to serious consequences that include worsening quality of life (Higginson & Costantini, 2008) , lower adherence to summarized in Table 2 and include study design, sample population, intervention, control, treatment length, outcomes, and adverse events. Study details of herbs for which there is currently only one RCT available are described in Table 3 .
| RESULTS
One hundred articles involving 38 botanicals were identified that met the inclusion criteria. They appear here in the order of most to least studied botanicals but appear alphabetically for ease of location in the tables. Among RCTs that met our criteria and had more than two RCTs (Table 2) , saffron, kava, ginkgo, lavender, brahmi, and passionflower appeared to be the most studied.
Saffron, derived from the stigma of Crocus sativus flower, is commonly used as a spice and as medicine in the Middle East and in South Asia. In patients with mild to moderate anxiety, extracts of saffron were reported to be effective in relieving symptoms in several RCTs (Akhondzadeh et al., 2005; Mazidi et al., 2016; Talaei, Hassanpour Moghadam, Sajadi Tabassi, & Mohajeri, 2015) . Studies also show that the effects are comparable to standard antidepressant drugs such as fluoxetine (Moosavi, Ahmadi, Amini, & Vazirzadeh, 2014; Noorbala, Akhondzadeh, Tahmacebi-Pour, & Jamshidi, 2005; Shahmansouri et al., 2014) and imipramine (Akhondzadeh, Fallah-Pour, Afkham, Jamshidi, & Khalighi-Cigaroudi, 2004 ). In addition, the less expensive petal extracts have also been tested and found to be effective substitutes (Akhondzadeh Basti et al., 2007; Akhondzadeh Basti, Choreishi, Noorbala, Akhondzadeh, & Rezazadeh, 2008; Movafegh, Alizadeh, Hajimohamadi, Esfehani, & Nejatfar, 2008) . Saffron reduced anxiety and depression scores in women with premenstrual syndrome as well (Agha-Hosseini et al., 2008) . Kava (Piper methysticum) originated from tropical islands and is used in traditional medicine. Dietary supplements containing kava extracts are promoted as a natural treatment for anxiety and insomnia. WS®1490, a standardized dry root extract, has been employed in several clinical trials (Gastpar & Klimm, 2003; Geier & Konstantinowicz, 2004; Malsch & Kieser, 2001; Volz & Kieser, 1997) and shown to have anxiolytic effects that were superior to placebo. Another extract demonstrated effects similar to those of buspirone and opipramol, prescription drugs used for anxiety and depression (Boerner et al., 2003) . Aqueous extracts of kava have also been investigated by Sarris et al. (2009) who reported their anxiolytic activity to be better than placebo with short-term (3 weeks) use but not as effective as oxazepam when given in acute doses for 1 week (Sarris et al., 2012) . In another study, this extract increased sexual drive in female users and reduced anxiety significantly .
Kava extract also reduced anxiety and depression scores in both perimenopausal (Cagnacci et al., 2003) and postmenopausal women (De Leo et al., 2000) .
Ginkgo biloba is an ancient plant recognized for its medicinal value throughout history and is cultivated around the world. The leaf extract is marketed as a dietary supplement to improve memory because it promotes blood flow. Quite a few clinical trials over the last two decades used EGB 761®, a standardized dry leaf extract of G. biloba. Note. In patients with cognitive impairment (Cieza, Maier, & Poppel, 2003; Gavrilova et al., 2014; Scripnikov, Khomenko, & Napryeyenko, 2007; van Dongen, van Rossum, Kessels, Sielhorst, & Knipschild, 2000) , this product was shown to be superior to placebo in relieving anxiety and depression. Similar findings were reported in patients with anxiety (Woelk, Arnoldt, Kieser, & Hoerr, 2007) or multiple sclerosis (Johnson et al., 2006) , with significant reductions in anxiety scores following use of EGB 761® compared to a placebo. However, results from a pilot study indicate that EGB 761® is no better than the prescription drug donepezil in Alzheimer's patients (Yancheva et al., 2009) , and another G. biloba extract (PN246) was no better than placebo in preventing seasonal affective depression (Lingaerde, Foreland, & Magnusson, 1999) .
The flower of lavender (Lavandula angustifolia) is used in perfumes and in aromatherapy because its fragrance has a purported calming effect. Oral supplements from this plant are also available for a wide variety of symptoms. Silexan®, a product derived from steam distillation of lavender flowers, has been tested in several human studies that
show its anxiolytic activity to be better than placebo (Kasper et al., 2010; Kasper et al., 2014; Kasper, Anghelescu, & Dienel, 2015) and comparable to prescription drugs such as paroxetine (Kasper et al., 2014 ) and lorazepam (Woelk & Schlafke, 2010) with fewer adverse effects. Lavender tea may also enhance the effect of the antidepressant citalopram (Nikfarjam, Parvin, Assarzadegan, & Asghari, 2013) .
Similar benefits were observed when lavender extract drops were taken with imipramine (Akhondzadeh et al., 2003) .
Brahmi (Bacopa monnieri) is a plant native to South Asia and commonly used in Ayurvedic medicine. Preliminary studies show that it acts as an acetylcholinesterase inhibitor suggesting it may benefit those with cognitive dysfunction. KeenMind®, an ethanolic extract derived from the stem, leaves, and root, was tested in adults in two studies. Results showed positive effects in improving cognitive function but not anxiety (Benson et al., 2014; Roodenrys et al., 2002) . Studies using other extracts showed a general reduction in anxiety scores (Calabrese et al., 2008; Kumar, Srivastav, Wahi, Singh, & Singh, 2011; Sathyanarayanan et al., 2013; Stough et al., 2001) . However, all studies were conducted only in healthy subjects with placebo controls.
Whether similar benefits could be conferred on patients with anxiety and depression and how this herb compares with standard medications for anxiety or depression remain unclear.
Passionflower is derived from the flower of Passiflora incarnata, a plant prevalent in Southeastern parts of the Americas. Native Americans used it as a remedy to improve sleep and to reduce anxiety.
One study that employed a traditional tea preparation taken before bedtime found that it can improve sleep quality but had no significant effect on anxiety when compared to a placebo (Ngan & Conduit, 2011 ). An aqueous extract of passionflower produced a slight but statistically significant improvement in anxiety scores in patients undergoing spinal anesthesia without disrupting psychomotor function or sedation (Aslanargun, Cuvas, Dikmen, Aslan, & Yuksel, 2012) . In another trial, a standardized P. incarnata extract was reported to reduce preoperative anxiety in patients undergoing inguinal herniorrhaphy (Movafegh et al., 2008) . When used as an adjuvant, passionflower extract improved mental symptoms more effectively than clonidine alone for opioid withdrawal (Akhondzadeh, Kashani, et al., 2001 ). In patients with anxiety disorder, passionflower extract was no better than oxazepam in reducing symptoms but had fewer adverse effects (Akhondzadeh, Naghavi, et al., 2001) . Similar findings were reported in another study that compared passionflower with sertraline (Nojoumi, Ghaeli, Salimi, Sharifi, & Raisi, 2017) .
Rhodiola (Rhodiola rosea) is a perennial plant used in traditional medicine in Asia and in Eastern Europe to improve physical endurance and mental performance. Results from studies of the root extract involving patients with anxiety (Cropley, Banks, & Boyle, 2015) and depression (Darbinyan et al., 2007) show that it can reduce symptoms when compared with placebo. In adults with stress-related fatigue, an R. rosea extract was no better than a placebo in reducing depression scores (Olsson, von Scheele, & Panossian, 2009) . A root extract was also less effective than the standard antidepressant drug sertraline in patients with mild to moderate depression but was associated with fewer adverse events and was better tolerated (Mao et al., 2015) .
Black cohosh (Cimicifuga racemosa) is an herb chiefly marketed for menopausal symptoms. But in a study of postmenopausal women, it was not as effective as fluoxetine in reducing depression, although it had a positive effect on hot flashes (Oktem et al., 2007) . Another study in the same population showed that a standardized black cohosh extract Remifemin® was as effective as low-dose transdermal estradiol treatment in reducing hot flashes, anxiety, and depression but without the hormonal changes exhibited with estradiol (Nappi, Malavasi, Brundu, & Facchinetti, 2005) . However, one trial that employed a different black cohosh extract did not find it more effective than a rice flour placebo (Amsterdam, Yao, et al., 2009 . A follow-up study of chamomile's long-term effects showed that it continued to be effective after 38 weeks although there was no significant reduction in relapse time (Mao et al., 2016) .
Guarana (Paullinia cupana) is an herb indigenous to South America.
Its extract is marketed as a dietary supplement mainly for its stimulant effects, which are likely due to the high caffeine content. However, in healthy volunteers, guarana was ineffective in reducing anxiety or improving well-being and mood (Silvestrini, Marino, & Cosentino, 2013) . In post-chemotherapy breast cancer patients, guarana was better than placebo in reducing fatigue but not anxiety or depression (de Oliveira Campos et al., 2011) . And in breast cancer patients undergoing radiation therapy, there were no significant differences in either Chasteberry (Vitex agnus castus) is often recommended for relief from premenstrual symptoms. Studies show that chasteberry drops are similar to placebo in relieving depressive symptoms (Zamani, Neghab, & Torabian, 2012) . When compared to fluoxetine, chasteberry was more effective in reducing physical symptoms, whereas fluoxetine was better for relieving psychological symptoms (Atmaca, Kumru, & Tezcan, 2003) .
Maca (Lepidium meyenii) is a plant indigenous to South America. It has been used to enhance fertility and sexual performance in both men and women and to relieve menopausal symptoms. Powdered roots (Stojanovska et al., 2015) as well as the dried methanolic extract (Brooks et al., 2008) have been tested on postmenopausal women in two studies with a crossover design. These products alleviated depression and anxiety without exerting hormonal effects.
Red clover (Trifolium pratense) is commonly used to address premenstrual and menopausal symptoms because it acts as a phytoestrogen. In studies of postmenopausal women, standardized T. pratense capsules were reported to relieve anxiety and related symptoms (Hidalgo, Chedraui, Morocho, Ross, & San Miguel, 2005; Lipovac et al., 2010 (Andreatini, Sartori, Seabra, & Leite, 2002) . When used as a sleep aid, its benefits and adverse event profile were comparable to oxazepam (Dorn, 2000) .
Wormwood (Artemisia absinthium) is used both as an herbal medicine and as a spice in alcoholic drinks. Two studies were conducted using SedaCrohn®, a standardized A. absinthium leaf and stem powder, in patients with Crohn's disease. When compared to standard medications (Krebs, Omer, & Omer, 2010) or a placebo (Omer et al., 2007) , this product improved depression symptom scores.
There were a number of herbal medicines for which our criteria yielded only one RCT (Table 3) .
American skullcap (Scutellaria lateriflora) has been compared with stinging nettle leaf (Urtica dioica folia) for its effects on improving mood in healthy participants (Brock, Whitehouse, Tewfik, & Towell, 2014) .
No significant differences were found, but this may be due to low levels of anxiety at baseline.
Flax oil is derived from the seed of Linum usitatissimum. Flax oil containing alpha-linolenic acid (α-LNA) was reported to be similar to olive oil in reducing depressive symptoms in children and young adults with bipolar disorder (Gracious et al., 2010) .
Garlic (Allium sativum) has been investigated in a study to determine its cholesterol-lowering activity. Psychopathologic parameters including depression were also evaluated, but no changes were observed (Peleg et al., 2003) .
Sage (Salvia officinalis) is generally used as a spice. Essential oil and extracts of sage are thought to inhibit cholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine. In a study that compared different dosages of a dried leaf extract with placebo, a lower dose (300 mg/d) was more effective than the higher dose (600 mg/d) in reducing anxiety in healthy young adults (Kennedy et al., 2006) .
In menopausal women, extracts of blue green algae (Aphanizomenon flos-aquae) (Genazzani et al., 2010) , Cimicifuga foetida (Zheng et al., 2013) Extracts from gotu kola (Centella asiatica; Bradwejn, Zhou, Koszycki, & Shlik, 2000) , green tea (Camelia sinensis; Zhang et al., 2013) , holy basil (Ocimum sanctum; Sampath, Mahapatra, Padhi, Sharma, & Talwar, 2015) , and Sceletium tortuosum (Terburg et al., 2013 ) when administered to healthy adults were more effective than placebo in reducing anxiety and/or depression scores.
Bitter orange blossom (Citus aurantium; Akhlaghi et al., 2011) , curcumin (Curcuma longa; Yu, Pei, Zhang, Wen, & Yang, 2015) , Melissa officinalis (Alijaniha et al., 2015) , and Siberian Ginseng (Eleutherococcus senticosis; Schaffler, Wolf, & Burkart, 2013) were also found to have some benefit in lowering anxiety and depression in clinical studies, but these symptoms were not the primary endpoints.
Ashwagandha (Withania somnifera; Chengappa et al., 2013) , black cumin (Nigella sativa; Bin Sayeed et al., 2014), and Chlorella vulgaris (Panahi, Badeli, Karami, Badeli, & Sahebkar, 2015) were not effective in relieving anxiety and depression in patients with related symptoms.
| DISCUSSION
In this review, we found that the majority were early phase studies, with no phase III trials. Study designs varied considerably with subjects including menopausal women and patients with anxiety disorders.
Some studies that used healthy volunteers with low baseline symptom levels may have produced misleading results. Anxiety or depressive symptoms were measured in all the studies but were not always the primary endpoints. In addition, different scales were used to measure the severity of symptoms. We chose to include only RCTs to reduce bias. Most trials used placebos or standard pharmaceutical agents in the control group. Overall, 45% of studies reviewed indicate significant improvements in anxiety or depression scores. Many studies that compared the effects of herbs with standard pharmaceutical agents reported that herbs are not as potent but are safer than prescription drugs. These include saffron (Akhondzadeh Basti et al., 2007; Moosavi et al., 2014; Noorbala et al., 2005; Shahmansouri et al., 2014) , black cohosh (Nappi et al., 2005; Oktem et al., 2007) , and chasteberry (Atmaca et al., 2003) . These herbs did not outperform fluoxetine but were associated with fewer adverse events, which can include changes in appetite, sexual dysfunction, nausea, headache, insomnia, and tremors.
Although several studies reported herbal supplements to be safe, their potential for interactions with other drugs were not discussed. For example, black cohosh (Li et al., 2011) , chasteberry (Ho, Singh, Holloway, & Crankshaw, 2011), chamomile (Ganzera, Schneider, & Stuppner, 2006) , and rhodiola (Hellum et al., 2010) are known to modulate the actions of cytochrome P450 enzymes and may increase the toxicity or decrease therapeutic effects of substrate drugs (Gurley, Fifer, & Gardner, 2012) including many used in cancer treatment, such as cyclosporine (Sridharan & Sivaramakrishnan, 2016) and most of the tyrosine kinase inhibitors (Gay, Toulet, & Le Corre, 2017) . Even though the clinical significance of these interactions is yet to be determined, the potential exists and therefore should be given due consideration. In addition, herbs such as chamomile (Segal & Pilote, 2006) and lavender (Denner, 2009 ) have anticoagulant/antiplatelet properties and may therefore elevate the risk of bleeding with concurrent use of drugs that have similar actions (Ge, Zhang, & Zuo, 2014) . These include warfarin and heparin drugs that are often used to treat or prevent deep vein thrombosis in bedridden cancer patients. These herbs may also further increase the cardiovascular complication of antiangiogenic drugs such as bevacizumab (Totzeck, Mincu, & Rassaf, 2017) . In addition, the debate continues about phytoestrogenic herbs that include lavender (Diaz, Luque, Badar, Kornic, & Danon, 2016) and chasteberry (Dugoua, Seely, Perri, Koren, & Mills, 2008) and their potential for interference with antihormonal therapies or for exerting proproliferative effects in patients with hormone-sensitive cancers (Fritz et al., 2013) . It is prudent to understand these risks because cancer patients often tend to use herbal products concomitantly with prescription drugs. Another concern is the intrinsic toxicity associated with some herbs. For instance, kava is a traditional herbal remedy with proven anxiolytic and antidepressant properties but has been associated with hepatotoxicity (Teschke, 2010) . This can be detrimental for cancer patients who often have compromised liver function as a side effect from chemotherapy (Vincenzi et al., 2016) .
However, aqueous extracts were reported to be safe in preclinical testing (Sarris et al., 2009; .
Clinical trials are needed to determine safety in humans.
Based on these data, black cohosh, chamomile, chasteberry, lavender, passionflower, and saffron appear to be worthy of consideration for the treatment of depression and anxiety with minimal risk of serious side effects. They appear to be reasonable options for patients who prefer a natural approach. Future research efforts should focus on elucidating the mechanisms of action as well as the safety and efficacy of these herbs. Also, clinical trials should employ wellcharacterized standardized agents. Optimal dosages, potential interactions, and adverse effects should be determined in early phase trials, preferably in cancer survivors.
Other limitations of this review include significant variability among the studies included along with publication bias, as many trials were sponsored by the manufacturers, and employed proprietary products.
| CONCLUSIONS
Available evidence suggests utility of some herbal medicines in mitigating anxiety and depression, but conclusive data to show superiority in benefit/risk ratio of these products over current pharmaceuticals are lacking. Due to the heterogeneity of previous trials, future studies should focus on using the standardized forms of these products in large-scale trials with robust methodology to determine their comparative effectiveness. A just-published review reported increased participation in studies with longitudinal design compared to randomized trials (Wakefield et al., 2017) . Studies to elucidate mechanisms and pharmacokinetics are also needed. The findings can help establish reliable dosage guidelines and effectiveness of herbal products, which appear to have a better benefit-to-risk profile than standard pharmacologic options. Cancer patients, known to have higher rates of depression and anxiety, might especially benefit from such research as conventional management is often not favorable.
